TXMD News and Press, TherapeuticsMD Inc. From 08/04/21

- 2Q21 total net product revenue increased by 17% over 1Q21 to $23 million - - ANNOVERA ® prescription growth supported by improved access to providers and increased telemedicine options for patients - - Prescriptions for IMVEXXY® grew by 8% over 1Q21, outpacing th...

Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...

-Executive Management to Host Conference Call on August 4, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2...

TherapeuticsMD Inc. (NASDAQ:TXMD) traded today at a new 52-week low of $0.93. This new low was reached on below average trading volume as 728,000 shares traded hands, while the average 30-day volume is approximately 5.9 million shares. TherapeuticsMD Inc is a major drug manufacturing wit...

Although the market did not take favorably to recent Q1 numbers, there were some encouraging trends. ANNOVERA continues to execute as marketing strategies continue to build awareness. Costs came down significantly in Q1 and sales grew by over 60%. We need more of the same going fo...

Deerfield Management has disclosed a 4.9% stake in TherapeuticsMD ([[TXMD]] -1.3%).The firm now owns 20,662,810 shares.TherapeuticsMD is focused on women's health drugs. For further details see: Deerfield Management discloses 4.9% stake in TherapeuticsMD

At the conclusion of the 2021 Russell indexes annual reconstitution, following notable healthcare stocks will join the Russell Microcap Index, effective June 28 after the U.S. market opens.Asensus Surgical (ASXC), Organovo Holdings (ONVO), Senseonics Holdings (SENS), Clovis Onc...

Pluristem Therapeutics (TXMD) shares are up more than 7% after an injection of €20M of funding (~$24M) from the European Investment Bank ("EIB").The disbursement is the first of three tranches of funding released due to meeting a milestone.The funds, which Pluristem expe...

TherapeuticsMD (TXMD) announces that it has submitted a supplemental New Drug Application (“sNDA”) to the FDA for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg.In approximately 74 days from the submission, the company is expected to learn about the accept...

BOCA RATON, Fla.--(BUSINESS WIRE)--May 24, 2021-- TherapeuticsMD, Inc. (NASDAQ: TXMD), has been awarded a Top Workplaces 2021 honor by The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner En...